Astrana Health, Inc. (NASDAQ:ASTH) Receives Consensus Rating of “Buy” from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $61.20.

ASTH has been the topic of several recent analyst reports. Truist Financial raised their price objective on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus raised their target price on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Robert W. Baird boosted their price target on shares of Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a report on Thursday, August 15th. Finally, BTIG Research boosted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday.

Astrana Health Stock Up 1.4 %

ASTH stock traded up $0.79 during midday trading on Thursday, reaching $58.66. 10,728 shares of the company’s stock traded hands, compared to its average volume of 189,340. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.62. The firm’s fifty day moving average price is $50.83 and its 200-day moving average price is $44.29. Astrana Health has a 52 week low of $28.86 and a 52 week high of $58.84. The company has a market cap of $3.29 billion, a price-to-earnings ratio of 44.30, a P/E/G ratio of 2.15 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.01. The firm had revenue of $486.30 million during the quarter, compared to analyst estimates of $440.68 million. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The company’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS. As a group, sell-side analysts forecast that Astrana Health will post 1.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Astrana Health stock. Central Pacific Bank Trust Division purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,753 shares of the company’s stock, valued at approximately $160,000. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.